We are live on ! Find out more
TAK icon

Takeda Pharmaceutical

302 hedge funds and large institutions have $1.02B invested in Takeda Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 118 increasing their positions, 84 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,086% more call options, than puts

Call options by funds: $28.2M | Put options by funds: $2.37M

68% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 28

40% more repeat investments, than reductions

Existing positions increased: 118 | Existing positions reduced: 84

6% more funds holding

Funds holding: 285 → 302 (+17)

0.11% more ownership

Funds ownership: 2.3% → 2.4% (+0.11%)

46% less capital inflows, than outflows

Capital inflows: $170M | Capital outflows: $315M

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
302
Holders Change
+17
Holders Change %
+5.96%
% of All Funds
4.32%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
47
Increased
118
Reduced
84
Closed
28
Calls
$28.2M
Puts
$2.37M
Net Calls
+$25.8M
Net Calls Change
+$5.28M

TAK Hedge Fund Activity: Q3 2024 in Review

302 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2024, worth a combined $1.02B — down 11% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new TAK positions and 28 closed out — a net gain of 19 holders — while 118 added to existing stakes and 84 trimmed.

The largest buyer was First Trust Advisors, opening a new position worth an estimated $45.1M. The largest seller was Groupama Asset Management, exiting entirely with an estimated $204M sold.

  • 302 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2024, up from 285 in Q2 2024.
  • Funds reported $1.02B of Takeda Pharmaceutical stock for Q3 2024, down 11% quarter-over-quarter.
  • 47 funds opened new Takeda Pharmaceutical positions in Q3 2024 and 28 closed out, a net change of +19 holders.
  • The largest Takeda Pharmaceutical buyer in Q3 2024 was First Trust Advisors, an estimated $45.1M added.
  • The largest Takeda Pharmaceutical seller in Q3 2024 was Groupama Asset Management, an estimated $204M sold.

Based on aggregated 13F filings for Q3 2024.